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Chronic kidney disease (CKD) affects approximately 500 million people worldwide and is increasingly
common in both industrialized and emerging countries. Although the mechanisms underlying the inexorable
progression of CKD are incompletely defined, recent discoveries may pave the way to a more comprehensive
understanding of the pathophysiology of CKD progression and the development of new therapeutic strategies.
In particular, there is accumulating evidence indicating a key role for the complex and yet incompletely
understood system of divalent cation regulation, which includes phosphate metabolism and the recently
discovered fibroblast growth factor 23 (FGF-23)/klotho system, which seems inextricably associated with
vitamin D deficiency. The aim of this review is to discuss the links between high blood pressure, proteinuria,
phosphate levels, and CKD progression and explore new therapeutic strategies to win the fight against CKD.
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aware of the disease until death is imminent and
kidney replacement therapy (dialysis or kidney trans-
plantation) is unavoidable. Unfortunately, 10% of
people requiring replacement therapy have access to
it, and more than 1 million people worldwide die of
untreated kidney failure each year because dialysis or
kidney transplantation is unaffordable in most coun-
tries. This represents a huge economic burden, with
global costs from 2000-2010 surpassing $1 trillion.1,2
Worsening kidney function is associated with a
marked increase in cardiovascular morbidity and mor-
tality1,3 independent of other risk factors. Coexistent
hypertension is present in 80% of patients with
CKD and worsens cardiovascular outcomes because
only 64% of patients with CKD achieve adequate
blood pressure control.4 As a consequence, only a
minority of the hundreds of thousands of patients with
stages 3 and 4 CKD reach kidney failure.5 Proteinuria
also is an important prognostic factor in patients with
CKD. Although patients with nonproteinuric CKD are
at greater risk of cardiovascular mortality than progres-
sion to kidney failure, the opposite may be true for the
presence of proteinuria. Patients from the REIN
(Ramipril Efficacy in Nephropathy) Study who were
in the highest tertile of baseline proteinuria (protein
excretion 3.8 g/d) also experienced the highest rate
of glomerular filtration rate (GFR) loss during follow-
up.6
In addition, although post hoc analysis of RENAAL
(Reduction of Endpoints in NIDDM [Non–Insulin-
Dependent Diabetes Mellitus] With the Angiotensin II
Antagonist Losartan) showed that 85% of patients
Am J Kidney Dis. 2013;xx(x):xxxwith proteinuria with protein excretion3 g/d reached
the composite end point of doubling of serum creati-
nine level or end-stage renal disease (ESRD), only
44% of these patients reached the composite cardiovas-
cular outcome.7
Besides the well-established role of hypertension
and proteinuria in the progression of CKD, accumulat-
ing evidence indicates a key role for the complex and
incompletely understood system of divalent cation
regulation, which includes phosphate metabolism and
the recently discovered fibroblast growth factor 23
(FGF-23)/klotho system, which seems inextricably
associated with vitamin D deficiency.
The aim of this review article is to emphasize the
links between 2 traditional factors of CKD progres-
sion, blood pressure and proteinuria (here identified as
the first 2 “P” factors for progression), and the more
recent subject of phosphate (the third “P” for progres-
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Cozzolino et alsion) in light of recent findings from experimental and
interventional studies.
BLOOD PRESSURE: THE FIRST “P” FOR
CKD PROGRESSION
Hypertension, the leading cause of death world-
wide,8 may be either a consequence or a cause of
CKD9 and is a major independent risk factor for both
kidney disease and faster rate of GFR loss.10,11 An
increased risk of ESRD beginning at the third quintile
of systolic and diastolic blood pressure (127/82 mm
Hg) was evident in 332,544 middle-aged men in the
Multiple Risk Factor Intervention Trial (MRFIT),10
and blood pressure values higher than high normal
were associated with a progressive increase in risk of
ESRD in the Okinawa mass screening program (n 
98,759).11 There is a large body of evidence that
blood pressure reduction may slow GFR loss and
reduce cardiovascular outcomes.12 However, 2 cru-
cial issues in the management of hypertension in
patients with CKD are first, whether a specific blood
pressure target may maximize renoprotection, and
second, whether a specific drug may be beneficial,
independent of blood pressure control. Concerning
blood pressure targets, few randomized trials13-16 have
been conducted in patients with CKD to confirm the
association of findings from these cohort studies.10,11
In the Modification of Diet in Renal Disease (MDRD)
Study, the largest randomized prospective trial per-
formed to date (840 patients, mostly with nondiabetic
kidney disease), tight blood pressure control (mean
arterial pressure 92 mm Hg; ie, blood pressure,
125/75 mm Hg) did not improve the primary outcome
of GFR reduction, doubling of serum creatinine level,
or ESRD.13 However, intensive control slowed the
progression of CKD when protein excretion1 g/d,17
although the greater benefits in GFR decline in these
patients may be explained in part by the greater use of
angiotensin-converting enzyme (ACE) inhibitors.
Similarly, a lower blood pressure goal did not signifi-
cantly reduce the rate of the composite outcome (GFR
reduction 50%, ESRD, or death) or the mean GFR
slope in 1,094 African American hypertensive pa-
tients with mild to moderate CKD from the African
American Study of Kidney Disease and Hypertension
(AASK),15 although a trend favoring the lower blood
pressure target again was evident in the subgroup with
a urinary protein-creatinine ratio 0.22 g/g at base-
line (urinary protein excretion300 mg/d).
In AASK, the ACE inhibitor ramipril afforded 22%
and 38% greater reductions in the composite outcome
compared to metoprolol and amlodipine, respectively.
However, the REIN-2 Study highlights that achieving
intensive blood pressure control by add-on therapy
with the dihydropyridine calcium channel blocker
2felodipine on top of ramipril was not beneficial in
patients with nondiabetic kidney disease, probably
because tighter blood pressure control was not accom-
panied by a reduction in intraglomerular pressure and
proteinuria.16 Thus, renin-angiotensin-aldosterone sys-
tem (RAAS)-blocking agents appear to be the key
component of renoprotective therapy rather than tight
blood pressure control because lowering blood pres-
sure to 130/80 mm Hg does not offer additional
renoprotection when achieved with drugs not affect-
ing the RAAS or in patients without significant protein-
uria or diabetes.18 The antiproteinuric properties of
RAAS-blocking agents were discovered first by Ander-
son et al19 and originally attributed to the hemody-
namic effects of reduced intraglomerular pressure
through preferential dilation of kidney arterioles. More
recently, evidence has been provided that RAAS-
blocking agents also ameliorate glomerular sieving
function by directly restoring slit diaphragm integrity
and increasing negative charge on the glomerular
membrane.20 After the landmark trial on the use of
captopril in diabetic kidney disease conducted by the
Collaborative Study Group,21 several clinical trials
demonstrated that RAAS-blocking agents may effec-
tively maximize reno- and cardioprotection5,22 in both
diabetic and nondiabetic nephropathies.23-30
PROTEINURIA: THE SECOND “P” FOR
CKD PROGRESSION
In healthy adults, urinary protein excretion does not
exceed 150 mg/d.31 Until recently, for patients with
proteinuria, protein excretion 1 g/d was considered
an optimal clinical target due to the low rate of
progression toward kidney failure.32
More recently, levels of proteinuria as low as pro-
tein excretion of 150-500 mg/d are regarded as a risk
factor for progression of kidney disease33 and cardio-
vascular mortality.22,34 Both epidemiologic31,35-37 and
interventional studies6,15,17 consistently show a strong
and independent association between increasing val-
ues of proteinuria and the risk of progression of
kidney disease in both diabetic and nondiabetic pa-
tients. Proteinuria was the most powerful predictor of
ESRD in a general population screening of more than
100,000 Japanese individuals followed up for 10
years.35 This strong and graded relationship also was
evident for mild increases in protein excretion on
dipstick urinalysis. Similar results were evident in a
post hoc observational analysis of MRFIT. Dipstick
proteinuria with protein excretion of 1 or 2 was
associated with a greater risk of ESRD over 25 years
of follow-up (hazard ratios of 3.1 and 15.7, respec-
tively).37 Moreover, high-normal values of urinary
albumin excretion were associated independently with
the onset of microalbuminuria or decreased kidney
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normoalbuminuria from the UK Prospective Diabetes
Study (UKPDS 74).38 Finally, a relationship between
higher baseline proteinuria and faster reduction in
GFR was found in the MDRD Study, as well as the
AASK and REIN trials.6,15,17 The latter study also
demonstrated that residual proteinuria reliably pre-
dicted long-term kidney prognosis regardless of blood
pressure control and treatment randomization and
independent of initial values of proteinuria and its
reduction during follow-up.39
Proteinuria also is a strong predictor of cardiovascu-
lar risk40,41 independent of level of kidney func-
tion.3,42 In a meta-analysis of 10 cohorts involving
266,975 people at increased risk of CKD, lower GFR
and higher albuminuria predicted cardiovascular dis-
ease and all-cause mortality independently of each
other.43 This independent association between any
level of proteinuria and total or cardiovascular mortal-
ity was confirmed in more than 1.1 million people
with proteinuria identified only by detection of “trace”
or greater levels following dipstick analysis34 and in
more than 100,000 individuals with an albumin-
creatinine ratio10 mg/g.22 In light of these findings,
all attempts have been made to reduce proteinuria by
any therapeutic means, including RAAS-blocking
agents, low salt intake,44 smoking cessation, optimal
metabolic control, and 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors.45 Multiple therapies
aimed at reducing proteinuria may slow the progres-
sion of kidney disease to a greater extent than any
single treatment. This was demonstrated effectively
by a multimodal intervention strategy, the Remission
Clinic program, that used all available lifestyle recom-
mendations and pharmacologic tools to further reduce
proteinuria in patients with CKD and severe protein-
uria already treated with RAAS-blocking agents.46-47
We recently confirmed the beneficial effects of this
strategy in patients with Alport syndrome.48
PHOSPHATE: THE THIRD “P” FOR
CKD PROGRESSION
Seminal observations by Ibels et al49 showed that
dietary phosphate restriction prevented proteinuria,
kidney calcifications, histologic changes, functional
deterioration, and deaths in a murine remnant-kidney
model. These findings were confirmed later in patients
with CKD treated with a low-phosphorus low-
nitrogen diet.50 A recent post hoc analysis of the REIN
Study has further expanded the role of phosphate in
CKD progression.51 The study had a dual objective:
(1) assess the relationship between phosphate levels at
inclusion and the incidence of kidney events, and (2)
assess whether the protective effect conferred by
ramipril on disease progression could be altered by
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increase of only 1 mg/dL in serum phosphate level,
irrespective of other risk factors, was associated with
an 85% increase in risk of progression to ESRD.
Moreover, patients in higher quartiles of serum phos-
phate levels showed a significantly lower protective
effect from ACE-inhibitor therapy. In patients with
serum phosphate levels 4.5 mg/dL, ACE-inhibitor
therapy brought almost no benefit. The interactions
observed between serum phosphate level, ACE inhibi-
tion, and GFR loss did not change appreciably after
adjustment for potential confounders, pointing to a
specific pathogenic role for this metabolic imbalance
in the progression of CKD.
CROSS-TALK AMONG THE 3 “PS” IN THE
PATHOGENESIS OF CKD PROGRESSION:
WHAT IS ALREADY KNOWN
Dysregulation of phosphate homeostasis may en-
sue in early stages of CKD long before an increase
in serum phosphorus levels. Although phosphate ho-
meostasis previously was thought to be regulated
exclusively by 1,25-dihydroxyvitamin D3 (calcitriol)
and parathyroid hormone, the FGF-23/klotho system
is now considered the main phosphate-regulating en-
docrine axis.52 In the remnant-kidney model of CKD
progression,27 surviving nephrons must excrete an
increasing amount of phosphate to maintain normal
phosphate levels. This issue is exacerbated further by
high dietary phosphate intake, with phosphate bioavail-
ability playing a central role.53-55 Prolonged phos-
phate load, rather than plasma levels, has been shown
to increase serum FGF-23 levels in nephrectomized
rats,56 suggesting that circulating phosphorus may not
adequately reflect phosphorus balance. Through FGF-
23–mediated mechanisms, phosphorus also may have
an inhibitory effect on the production of nitric ox-
ide,57 which could reduce or prevent the beneficial
effects mediated by nitric oxide activation during
ACE-inhibitor therapy. However, the molecular
mechanisms underlying the association between pro-
longed phosphate load and increased levels of FGF-
23, which is secreted mainly by bone cells,58 are
largely unknown. The responsiveness of FGF-23 to
dietary phosphate is sluggish (hours to days),59 and
phosphate does not directly stimulate FGF-23 expres-
sion in osteoblast cultures,60 emphasizing the impor-
tance of other local or systemic regulators.61 Higher
FGF-23 levels increase urinary phosphate excretion
by suppressing the expression of the sodium-depen-
dent phosphate cotransporters NPT2a and NPT2c in
the kidney proximal tubule61 and reduce phosphorus
absorption in the gut by decreasing calcitriol levels.
Unfortunately, lower calcitriol levels also stimulate
the RAAS through increased renin production and the
3
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Cozzolino et altransforming growth factor  (TGF-)–converting
enzyme/TGF-/epidermal growth factor (EGF) recep-
tor pathway (Fig 1), leading to an increase in inflam-
mation, urinary protein excretion, and fibrosis. This
ultimately accelerates the progression of kidney dam-
age and increases the risk of cardiovascular events.62-65
FGF-23 also exhibits direct end-organ toxicity on the
myocardium and may be involved in the pathogenesis
of left ventricular hypertrophy and uremic cardiomy-
opathy.66 Lower calcitriol levels also increase parathy-
roid hormone secretion, which in turn stimulates
FGF-23 synthesis67 and TGF- secretion,68 thus gen-
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FGF-23 levels. The latter reduces calcitriol levels
and further activates the RAAS. Of note, restora-
tion of klotho by gene transfer improves angioten-
sin II–induced proteinuria.70
As this discussion attests, the FGF-23/klotho sys-
tem is strongly connected with the RAAS (Fig 1).
Abnormal activation of the systemic and local RAAS
is found commonly in patients with CKD and deeply
influences medium- to long-term control of both blood
pressure and proteinuria. Among its well-known hemo-
dynamic and nonhemodynamic detrimental effects,
angiotensin II also activates the TGF-–converting
enzyme/TGF-/EGF receptor pathway,71 which may
exacerbate proteinuria and kidney fibrosis. This may
occur through the release of proinflammatory and
profibrotic cytokines,72 including adhesion mol-
ecules,73,74 and reduced vitamin D receptor cell-
surface expression.68
The cross-talk between phosphorus metabolism,
the FGF-23/klotho system, and the RAAS may contrib-
ute to the initiation and progression of chronic protein-
uric nephropathies that are characterized by a loss of
selectivity of the glomerular filtration barrier. In this
respect, a recent study highlighted the key role of
podocyte detachment and the loss of normal endothe-
lial cell fenestration in 37 patients with type 2 diabetes
undergoing kidney biopsy. The percentage of podo-
cyte detachment correlated positively with urinary
albumin excretion and negatively with number of
podocytes per glomerulus. The percentage of endothe-
lial cell fenestration was associated negatively with
glomerular basement membrane width and fractional
interstitial and mesangial area and positively with
filtration surface area density and GFR. Increasing
podocyte detachment is associated with decreased
permselectivity of the glomerulus and progressive
albuminuria, whereas loss of endothelial cell fenestra-
tion is associated with GFR decline.75 These findings
are supportive of previous research in the same field,76
recapitulated in a recent review.77 Higher levels of
proteinuria may increase the release of profibrotic,
proinflammatory, and vasoactive molecules78-82 with
consequent oxidative stress, tubulointerstitial fibrosis,
and loss of functional nephrons (Fig 1).83 These
changes cause further nephron injury, increased intra-
glomerular pressure, impaired filter function, and
further loss of proteins in urine, with concomitant
activation of the complement cascade.27,84-86 Pro-
gressive nephron loss also causes severe impair-
ment of the Nrf2-Keap1 (nuclear factor erythroid
2–related factor 2/kelch-like ECH-associated pro-
tein 1) pathway, with increased oxidative stress and
inflammation.87,88 Inflammation and oxidative stress
are linked inseparably and represent major media-
Am J Kidney Dis. 2013;xx(x):xxxtors of CKD progression and the associated cardio-
vascular complications.62,70,81,89
INSIGHTS FROM RECENT EXPERIMENTAL STUDIES
AND NOVEL THERAPEUTIC TARGETS
In patients with CKD, the vicious cycle between
phosphorus metabolism, the FGF-23/klotho axis, and
the RAAS likely is activated even in the presence of
serum phosphate levels within the normal range. Di-
etary phosphate restriction can significantly lower
FGF-23 levels53-55 and could be more effective if
started before serum phosphate levels increase. Vita-
min D receptor agonists may effectively inhibit both
the TGF-–converting enzyme/TGF/EGF receptor
pathway and the RAAS in the parathyroid and kid-
ney90,91 and reduce vascular calcification, podocyte
damage,63,92-94 and proteinuria through blockade of
Wnt/-catenin signaling.95 Vitamin D receptor ago-
nists also may upregulate klotho96 and exert an anti-
inflammatory action through the reduction of nuclear
factor B. These actions may explain in part the
nephroprotective effects and reduced mortality ob-
served in patients treated with vitamin D receptor
agonists independent of serum 25-dehydroxyvitamin
D levels.97-101 Non–calcium-based phosphate binders
may correct hyperphosphatemia and ameliorate abnor-
malities of the mineral metabolism associated with
accelerated kidney disease progression and increased
cardiovascular risk.102-104 The finding that phosphate
binders reduced proteinuria, an effect that appears to
be associated with significant renoprotection in the
long term according to recent animal studies (Fig
2),105,106 along with results of the post hoc analysis of
the REIN Study,51 can be taken to suggest that strate-
gies aimed at lowering phosphate levels might be used
in the future to maximize the renoprotective effects of
RAAS-blocking agents.
FUTURE PERSPECTIVES
In summary, the complex interactions among the
different pathways of CKD progression may explain
why the specific renoprotective effects of traditional
RAAS-blocking agents are blunted by serum phos-
phate levels 4.5 mg/dL. This is a major issue be-
cause RAAS inhibition currently is the standard
therapy for proteinuric nephropathies. In particular,
there is a need for additional randomized controlled
trials with longer follow-up and hard kidney end
points to evaluate the hypothesis that additional thera-
peutic interventions may be instrumental to improv-
ing renoprotection in this high-risk population. In this
respect, an ongoing trial will evaluate the renoprotec-
tive effects of serum phosphate reduction by noncal-
cium phosphate binders in patients with CKD with
5
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Cozzolino et alreference serum phosphate levels and residual protein-
uria despite optimal RAAS-inhibitor therapy accord-
ing to the Remission Clinic approach.
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